Fiorino, Gionata
 Distribuzione geografica
Continente #
EU - Europa 86
NA - Nord America 48
AS - Asia 35
OC - Oceania 6
AF - Africa 4
SA - Sud America 1
Totale 180
Nazione #
US - Stati Uniti d'America 46
IT - Italia 41
GB - Regno Unito 12
IN - India 9
AU - Australia 6
JP - Giappone 6
NL - Olanda 5
UA - Ucraina 5
CZ - Repubblica Ceca 4
HK - Hong Kong 4
CY - Cipro 3
RO - Romania 3
SG - Singapore 3
BA - Bosnia-Erzegovina 2
CA - Canada 2
CN - Cina 2
ES - Italia 2
ET - Etiopia 2
GR - Grecia 2
LB - Libano 2
MY - Malesia 2
PL - Polonia 2
PT - Portogallo 2
AE - Emirati Arabi Uniti 1
BE - Belgio 1
DE - Germania 1
DZ - Algeria 1
EC - Ecuador 1
EE - Estonia 1
HR - Croazia 1
IE - Irlanda 1
IQ - Iraq 1
IR - Iran 1
NG - Nigeria 1
RS - Serbia 1
SA - Arabia Saudita 1
Totale 180
Città #
Milan 12
Abbiategrasso 8
Ashburn 6
Council Bluffs 5
Detroit 4
New Delhi 4
Acton 3
Messina 3
Nicosia 3
Revere 3
Boardman 2
Cary 2
Delhi 2
Kowloon 2
Kuala Lumpur 2
Melbourne 2
Modena 2
New York 2
Nottingham 2
Sarajevo 2
Tampines New Town 2
Tokyo 2
Toronto 2
Adelaide 1
Alcobendas 1
Almada 1
Atlanta 1
Bishop Auckland 1
Brasov 1
Bucharest 1
Central 1
Champaign 1
Clusone 1
Craiova 1
Dayton 1
Dubai 1
Dublin 1
Estarreja 1
Everett 1
Farrukhabad 1
Greenwich 1
Hobart 1
Hoogvliet 1
Kerpen 1
Liverpool 1
Magalia 1
Marousi 1
Matsudo 1
Needham 1
Newcastle upon Tyne 1
Ninove 1
Nuoro 1
Orlando 1
Osaka 1
Palo Alto 1
Perth 1
Phoenix 1
Port Harcourt 1
Providence 1
Pune 1
Quito 1
Richmond 1
Riyadh 1
Royal Oak 1
Saint Joseph 1
Santa Barbara 1
Shanghai 1
Shijiazhuang 1
Shrewsbury 1
Sunnyvale 1
Sydney 1
Tadworth 1
Tartu 1
Tehran 1
The Bronx 1
Thessaloniki 1
Tooting 1
Udine 1
Vadodara 1
Valencia 1
Valenzano 1
Warsaw 1
Westborough 1
Wilmington 1
Zagreb 1
Totale 139
Nome #
Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease, file de164a8e-c658-73f5-e053-d805fe0a7be4 48
Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease, file de164a8f-2e50-73f5-e053-d805fe0a7be4 37
Comparison between 1.5 and 3.0 Tesla magnetic resonance enterography for the assessment of disease activity and complications in ileo-colonic Crohn's disease, file de164a8f-25cf-73f5-e053-d805fe0a7be4 20
Prevalence of Bowel Damage Assessed by Cross-Sectional Imaging in Early Crohn's Disease and its Impact on Disease Outcome., file de164a8e-bc49-73f5-e053-d805fe0a7be4 9
OP018 High-fat diet and inflammation drive intestinal fibrosis enhancing epithelial–mesenchymal transition through the activation of S1P3 signalling, file de164a8f-15fc-73f5-e053-d805fe0a7be4 9
Bowel damage as assessed by the Lémann Index is reversible on anti-TNF therapy for Crohn's disease, file de164a8f-1ff7-73f5-e053-d805fe0a7be4 8
Infliximab therapy inhibits inflammation-induced angiogenesis in the mucosa of patients with Crohn's disease, file de164a8f-3390-73f5-e053-d805fe0a7be4 7
Rho-A prenylation and signaling link epithelial homeostasis to intestinal inflammation, file de164a8e-c45f-73f5-e053-d805fe0a7be4 6
Short-term outcomes of laparoscopy combined with enhanced recovery pathway after ileocecal resection for Crohn's disease : a case-matched analysis, file de164a8f-2079-73f5-e053-d805fe0a7be4 6
Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease : a prospective study, file de164a8f-2643-73f5-e053-d805fe0a7be4 5
Preoperative magnetic resonance enterography in predicting findings and optimizing surgical approach in Crohn's disease, file de164a8f-25ca-73f5-e053-d805fe0a7be4 3
The Role of Magnetic Resonance Imaging in Detecting Intestinal Fibrosis in Crohn's Disease, file de164a8f-2600-73f5-e053-d805fe0a7be4 3
COMPARATIVE ACCURACY OF US VERSUS MRI AND COLONOSCOPY IN ASSESSING DISEASE ACTIVITY AND COMPLICATIONS AND INFLUENCING THE DECISION-MAKING PROCESS IN CROHN'S DISEASE, file de164a8e-c113-73f5-e053-d805fe0a7be4 2
Review article: anti-fibrotic agents for the treatment of Crohn's disease - lessons learnt from other diseases, file de164a8e-bcfa-73f5-e053-d805fe0a7be4 1
Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease, file de164a8e-bea4-73f5-e053-d805fe0a7be4 1
Are Surgical Rates Decreasing in the Biological Era In IBD?, file de164a8e-bec5-73f5-e053-d805fe0a7be4 1
Calcium supplementation for the prevention of colorectal adenomas: a systematic review and meta-analysis of randomized controlled trials, file de164a8e-bfc7-73f5-e053-d805fe0a7be4 1
Dose Optimization Is Effective in Patients With Ulcerative Colitis Losing Response to Infliximab: A Collaborative Multicentre Retrospective Study, file de164a8e-c0f3-73f5-e053-d805fe0a7be4 1
Role of bowel ultrasound as a predictor of surgical recurrence of Crohn's disease, file de164a8e-c0f4-73f5-e053-d805fe0a7be4 1
Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients, file de164a8e-c1dc-73f5-e053-d805fe0a7be4 1
Infliximab in Steroid-Dependent Ulcerative Colitis: Efficacy and Predictors of Clinical and Endoscopic Remission, file de164a8e-c335-73f5-e053-d805fe0a7be4 1
ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment, file de164a8e-c34d-73f5-e053-d805fe0a7be4 1
Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease, file de164a8e-c4de-73f5-e053-d805fe0a7be4 1
The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy, file de164a8e-c4e0-73f5-e053-d805fe0a7be4 1
ECCO Guidelines on Therapeutics in Crohn's Disease: medical treatment, file de164a8e-c594-73f5-e053-d805fe0a7be4 1
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission, file de164a8e-c5b4-73f5-e053-d805fe0a7be4 1
New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease, file de164a8e-c5c0-73f5-e053-d805fe0a7be4 1
Antibodies to infliximab in patients treated with either the reference biologic or the biosimilar CT-P13 show identical reactivity towards biosimilars CT-P13 and SB2 in inflammatory bowel disease, file de164a8e-c743-73f5-e053-d805fe0a7be4 1
Stimulation of CYP450-mediated ω-3 docosahexaenoic acid metabolism via MFSD2A as a novel therapy for inflammatory bowel disease, file de164a8e-ffc6-73f5-e053-d805fe0a7be4 1
Emerging biologics in the treatment of inflammatory bowel disease : what is around the corner?, file de164a8f-29af-73f5-e053-d805fe0a7be4 1
Totale 180
Categoria #
all - tutte 754
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 754


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20206 0 0 0 0 0 0 0 0 0 0 0 6
2020/202111 0 0 2 6 0 0 0 0 2 0 0 1
2021/202213 1 0 2 0 1 0 0 0 1 0 1 7
2022/2023114 0 0 0 2 13 15 20 21 21 11 10 1
2023/202436 2 1 1 4 6 4 10 0 2 6 0 0
Totale 180